Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
| Заболевание | Melanoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| Статус | Завершено |
| Участники | 26 участн. |
| Вмешательство | Nivolumab |
| Дата начала | 17.01.2018 |
| Дата завершения | 15.12.2025 |
| Публикация результатов | 16.06.2026 |
Кратко
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Recurrence-free Survival
| Treatment (Nivolumab) | 87.8 percentage of participants |
|---|
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)